Amentum and Eagle Options Trading Activity Surges
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 31 2026
0mins
Should l Buy APLS?
Source: NASDAQ.COM
- Amentum Options Volume: Amentum Holdings Inc (AMTM) has seen an options volume of 16,953 contracts today, representing approximately 1.7 million shares, which constitutes 92.4% of its average daily trading volume of 1.8 million shares over the past month, indicating strong market interest in its future performance.
- High Volume Contracts: Within AMTM, the $20 strike call option is particularly active, with 15,688 contracts traded today, equating to about 1.6 million shares, suggesting that investors are optimistic about the stock's potential rise before its expiration in April 2026.
- Eagle Options Activity: Eagle Materials Inc (EXP) has recorded an options volume of 4,201 contracts today, representing approximately 420,100 shares, which is 88.7% of its average daily trading volume of 473,550 shares over the past month, reflecting ongoing market interest in its stock.
- EXP High Volume Contracts: For EXP, the $160 strike call option has seen 2,093 contracts traded today, amounting to about 209,300 shares, indicating that investors are anticipating potential upward movement in the stock before its expiration in November 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APLS
Wall Street analysts forecast APLS stock price to fall
14 Analyst Rating
9 Buy
5 Hold
0 Sell
Moderate Buy
Current: 40.870
Low
19.00
Averages
31.69
High
48.00
Current: 40.870
Low
19.00
Averages
31.69
High
48.00
About APLS
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating companies such as Globalstar, Inc., Apellis Pharmaceuticals, Inc., and Forian Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Transaction Details: Globalstar is being sold for $90 per share in cash or 0.3210 shares of Amazon stock, Apellis for $41 per share in cash plus two contingent value rights of $2 each, and Forian for $2.17 per share in cash, indicating varied transaction structures and associated risks.
- Shareholder Rights Protection: The firm encourages shareholders to contact them to discuss their rights and options at no upfront cost, aiming to provide legal support for affected shareholders and ensure their interests are represented.
- Legal Implications: The firm may seek increased consideration, additional disclosures, or other relief measures to protect shareholder rights, reflecting a commitment to corporate governance and transparency.
See More
Biogen Shares Rise After Upgrade and Acquisition Announcement
- Stock Price Surge: Biogen (BIIB) shares rose after Piper Sandler upgraded the stock from Neutral to Overweight, raising the price target from $174 to $214, reflecting positive market sentiment regarding its acquisition of eye drug developer Apellis Pharmaceuticals (APLS).
- Acquisition Deal: Biogen is set to complete the $5.6 billion acquisition of Apellis in Q2, which will enhance its Alzheimer's drug portfolio, with Apellis' Empaveli and Syfovre projected to generate $689 million in revenue by 2025, filling the revenue gap from the loss of exclusivity on its multiple sclerosis assets.
- Portfolio Integration: Analysts noted that by integrating Empaveli with an advancing immunology pipeline, Biogen is positioned to achieve “meaningful top-line growth” in the future, helping to offset potential declines in royalties linked to the MS therapy Ocrevus.
- Valuation Expansion Outlook: Piper analysts anticipate that Biogen's EV/2026E EBITDA multiple will expand from approximately 11x to 13x, indicating optimistic investor sentiment regarding the company's future growth potential and reflecting confidence in its profitability trajectory.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) regarding its sale to Biogen Inc. for $41.00 per share in cash and two contingent value rights of $2.00 each, potentially infringing on shareholder rights.
- Shareholder Rights Protection: The firm encourages Apellis shareholders to understand their legal rights and options, emphasizing free consultations to ensure that shareholder interests are protected in the transaction.
- Additional Company Investigations: Centessa Pharmaceuticals plc (NASDAQ:CNTA) is also under scrutiny for its sale to Eli Lilly for $38.00 per share plus a contingent value right of up to $9.00, with Halper Sadeh LLC investigating possible breaches of fiduciary duties.
- Legal Relief Measures: Halper Sadeh LLC represents investors globally, seeking increased consideration, additional disclosures, or other relief to advocate for the rights of affected shareholders.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Investigation Background: Halper Sadeh LLC is investigating companies like Apellis Pharmaceuticals, KORE Group Holdings, and Centessa Pharmaceuticals for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Apellis Transaction Details: Apellis Pharmaceuticals is being sold to Biogen Inc. for $41.00 per share in cash, along with a non-transferable right to receive two payments of $2.00 each, contingent on meeting specific global net sales thresholds, potentially affecting shareholder returns.
- KORE Transaction Situation: KORE Group Holdings is being sold for $9.25 per share to Searchlight Capital Partners and Abry Partners, prompting shareholders to consider the implications of this transaction on their rights and available legal options.
- Centessa Transaction Analysis: Centessa Pharmaceuticals is being sold for $38.00 per share in cash, plus a non-transferable right entitling holders to receive up to $9.00 upon achieving certain milestones, urging shareholders to understand their legal rights and options.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Affinity Bancshares, Inc. and Fidelity Bancshares, where Affinity shareholders are expected to receive $23.00 per share in cash, significantly impacting shareholder returns.
- Apellis Pharmaceutical Deal: In the transaction between Apellis Pharmaceuticals, Inc. and Biogen, Apellis shareholders are expected to receive $41.00 per share in cash along with two non-transferable rights of $2.00 each, providing additional potential earnings and enhancing investment appeal.
- Olaplex Acquisition Case: In the deal between Olaplex Holdings, Inc. and Henkel US Operations, Olaplex shareholders are expected to receive $2.06 per share in cash, offering direct cash returns to shareholders and boosting market confidence.
- KORE Group Transaction: In the transaction involving KORE Group Holdings, Inc. and Searchlight Capital Partners, KORE shareholders are expected to receive $9.25 per share in cash, providing substantial cash flow to shareholders and further solidifying their market position.
See More
Ademi LLP Investigates Apellis for Potential Fiduciary Breaches in Biogen Deal
- Investigation Launched: Ademi LLP is investigating Apellis for potential breaches of fiduciary duty in its transaction with Biogen, highlighting concerns over corporate governance that may impact shareholder confidence.
- Transaction Details: In this deal, Apellis shareholders will receive $41 per share in cash plus contingent value rights, with an additional $2 per share if SYFOVRE achieves $1.5 billion in annual sales from 2027 to 2030, indicating potential upside for investors.
- Sales Target Incentives: Should SYFOVRE reach $2 billion in sales in 2031, shareholders would receive an additional $4 per share, creating a performance-driven structure that could attract investor interest but also increases pressure on sales targets.
- Competition Restriction Clause: The transaction agreement imposes significant penalties for accepting competing bids, which may limit Apellis's strategic flexibility in the future, raising red flags for shareholders regarding governance and decision-making processes.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating companies such as Globalstar, Inc., Apellis Pharmaceuticals, Inc., and Forian Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Transaction Details: Globalstar is being sold for $90 per share in cash or 0.3210 shares of Amazon stock, Apellis for $41 per share in cash plus two contingent value rights of $2 each, and Forian for $2.17 per share in cash, indicating varied transaction structures and associated risks.
- Shareholder Rights Protection: The firm encourages shareholders to contact them to discuss their rights and options at no upfront cost, aiming to provide legal support for affected shareholders and ensure their interests are represented.
- Legal Implications: The firm may seek increased consideration, additional disclosures, or other relief measures to protect shareholder rights, reflecting a commitment to corporate governance and transparency.
See More
Biogen Shares Rise After Upgrade and Acquisition Announcement
- Stock Price Surge: Biogen (BIIB) shares rose after Piper Sandler upgraded the stock from Neutral to Overweight, raising the price target from $174 to $214, reflecting positive market sentiment regarding its acquisition of eye drug developer Apellis Pharmaceuticals (APLS).
- Acquisition Deal: Biogen is set to complete the $5.6 billion acquisition of Apellis in Q2, which will enhance its Alzheimer's drug portfolio, with Apellis' Empaveli and Syfovre projected to generate $689 million in revenue by 2025, filling the revenue gap from the loss of exclusivity on its multiple sclerosis assets.
- Portfolio Integration: Analysts noted that by integrating Empaveli with an advancing immunology pipeline, Biogen is positioned to achieve “meaningful top-line growth” in the future, helping to offset potential declines in royalties linked to the MS therapy Ocrevus.
- Valuation Expansion Outlook: Piper analysts anticipate that Biogen's EV/2026E EBITDA multiple will expand from approximately 11x to 13x, indicating optimistic investor sentiment regarding the company's future growth potential and reflecting confidence in its profitability trajectory.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) regarding its sale to Biogen Inc. for $41.00 per share in cash and two contingent value rights of $2.00 each, potentially infringing on shareholder rights.
- Shareholder Rights Protection: The firm encourages Apellis shareholders to understand their legal rights and options, emphasizing free consultations to ensure that shareholder interests are protected in the transaction.
- Additional Company Investigations: Centessa Pharmaceuticals plc (NASDAQ:CNTA) is also under scrutiny for its sale to Eli Lilly for $38.00 per share plus a contingent value right of up to $9.00, with Halper Sadeh LLC investigating possible breaches of fiduciary duties.
- Legal Relief Measures: Halper Sadeh LLC represents investors globally, seeking increased consideration, additional disclosures, or other relief to advocate for the rights of affected shareholders.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Investigation Background: Halper Sadeh LLC is investigating companies like Apellis Pharmaceuticals, KORE Group Holdings, and Centessa Pharmaceuticals for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Apellis Transaction Details: Apellis Pharmaceuticals is being sold to Biogen Inc. for $41.00 per share in cash, along with a non-transferable right to receive two payments of $2.00 each, contingent on meeting specific global net sales thresholds, potentially affecting shareholder returns.
- KORE Transaction Situation: KORE Group Holdings is being sold for $9.25 per share to Searchlight Capital Partners and Abry Partners, prompting shareholders to consider the implications of this transaction on their rights and available legal options.
- Centessa Transaction Analysis: Centessa Pharmaceuticals is being sold for $38.00 per share in cash, plus a non-transferable right entitling holders to receive up to $9.00 upon achieving certain milestones, urging shareholders to understand their legal rights and options.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Affinity Bancshares, Inc. and Fidelity Bancshares, where Affinity shareholders are expected to receive $23.00 per share in cash, significantly impacting shareholder returns.
- Apellis Pharmaceutical Deal: In the transaction between Apellis Pharmaceuticals, Inc. and Biogen, Apellis shareholders are expected to receive $41.00 per share in cash along with two non-transferable rights of $2.00 each, providing additional potential earnings and enhancing investment appeal.
- Olaplex Acquisition Case: In the deal between Olaplex Holdings, Inc. and Henkel US Operations, Olaplex shareholders are expected to receive $2.06 per share in cash, offering direct cash returns to shareholders and boosting market confidence.
- KORE Group Transaction: In the transaction involving KORE Group Holdings, Inc. and Searchlight Capital Partners, KORE shareholders are expected to receive $9.25 per share in cash, providing substantial cash flow to shareholders and further solidifying their market position.
See More
Ademi LLP Investigates Apellis for Potential Fiduciary Breaches in Biogen Deal
- Investigation Launched: Ademi LLP is investigating Apellis for potential breaches of fiduciary duty in its transaction with Biogen, highlighting concerns over corporate governance that may impact shareholder confidence.
- Transaction Details: In this deal, Apellis shareholders will receive $41 per share in cash plus contingent value rights, with an additional $2 per share if SYFOVRE achieves $1.5 billion in annual sales from 2027 to 2030, indicating potential upside for investors.
- Sales Target Incentives: Should SYFOVRE reach $2 billion in sales in 2031, shareholders would receive an additional $4 per share, creating a performance-driven structure that could attract investor interest but also increases pressure on sales targets.
- Competition Restriction Clause: The transaction agreement imposes significant penalties for accepting competing bids, which may limit Apellis's strategic flexibility in the future, raising red flags for shareholders regarding governance and decision-making processes.
See More
